Literature DB >> 21371244

Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.

Curtis A Pettaway1, Lois E Lamerato, Michael T Eaddy, Jessie K Edwards, Susan L Hogue, Martin M Crane.   

Abstract

OBJECTIVE: • To compare prostate cancer, prostate-related surgery and acute urinary retention rates, as well as associated healthcare resource use over 11 years in African American and Caucasian men with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: • The BPH-related medical and surgical charges and events were determined for 398 African American men and 1656 Caucasian men followed for a mean of 10.2 years within a health maintenance organization. • Racial differences in clinical outcomes were evaluated using time-to-event analysis, stratifying results by baseline prostate-specific antigen (PSA) values.
RESULTS: • Risk of a prostate cancer diagnosis was 2.2 times greater in African American than Caucasian men (95% CI 1.48-3.35, P < 0.001) in analyses adjusting for serum PSA level. • Although African Americans were more likely to receive medical therapy for symptoms of BPH than Caucasians (43.5% vs 37.2%, respectively; P= 0.029), there were no clinically meaningful differences with respect to subsequent acute urinary retention or BPH-related surgery between them, or BPH-related medical charges (US $407 vs US $405 per month).
CONCLUSION: • As evidenced by this analysis of 'real-world' clinical practice, African Americans with BPH have a much greater risk of developing prostate cancer than similar Caucasian men highlighting the need for education and early detection in this population.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371244     DOI: 10.1111/j.1464-410X.2010.09991.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

Review 1.  Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment.

Authors:  Brian C Jordan; Charlotta D Mock; Ramasamy Thilagavathi; Chelliah Selvam
Journal:  Life Sci       Date:  2016-03-24       Impact factor: 5.037

2.  Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Jeannette M Schenk; Gregory S Calip; Catherine M Tangen; Phyllis Goodman; J Kellogg Parsons; Ian M Thompson; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2012-06-28       Impact factor: 4.897

3.  Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative.

Authors:  Justin Loloi; Matthew Wei; Mustufa Babar; Denzel Zhu; Ethan B Fram; Pedro Maria
Journal:  Int Braz J Urol       Date:  2022 Jul-Aug       Impact factor: 3.050

4.  Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk.

Authors:  S-C Hung; S-W Lai; P-Y Tsai; P-C Chen; H-C Wu; W-H Lin; F-C Sung
Journal:  Br J Cancer       Date:  2013-04-23       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.